By Blake Brittain WASHINGTON (Reuters) -The U.S. Supreme Court on Monday declined to hear Novartis Pharmaceuticals Corp s bid to revive a key patent on its .
Holland & Knight Health Dose is an in-depth weekly dose of legislative and regulatory insights to keep stakeholders abreast of happenings in Washington, D.C., impacting the health sector.
Dr. Mark Moorman, Director of the Food and Drug Administration's (FDA) Office of Food Safety, and Stephen Hughes (Prevention Coordinator) published a post on the FDA Voices blog on October 13, 2022.
Novartis had asked the justices to suspend a lower court's ruling that lifted a ban on generic versions of Gilenya, the Switzerland-based company's third highest-selling drug last year with $2.8 billion in sales. Exclusive-NHS drafts stricter oversight of trans youth care England's National Health Service has drafted new guidelines for treating transgender youth that would call for local authorities to be alerted in some cases where young people have obtained puberty blockers and hormone therapies on the private market, according to a copy of the guidelines reviewed by Reuters.